Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Pharmaceutics Year : 2022

Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation

Claire Pressiat
Agathe Kudela
  • Function : Author
Quentin de Roux
  • Function : Author
Nihel Khoudour
Claire Alessandri
  • Function : Author
Hakim Haouache
  • Function : Author
Dominique Vodovar
  • Function : Author
Alice Hutin
Bijan Ghaleh
  • Function : Author
Anne Hulin
Nicolas Mongardon

Abstract

Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount for efficacy and absence of toxicity in critically ill patients. Amikacin is a major antibiotic used in nosocomial sepsis, especially for these patients. We aimed to describe amikacin pharmacokinetics on V-A ECMO support and to determine relevant variables to improve its dosing. All critically ill patients requiring empirical antimicrobial therapy, including amikacin for nosocomial sepsis supported or not by V-A ECMO, were included in a prospective population pharmacokinetic study. This population pharmacokinetic analysis was built with a dedicated software, and Monte Carlo simulations were performed to identify doses achieving therapeutic plasma concentrations. Thirty-nine patients were included (control n = 15, V-A ECMO n = 24); 215 plasma assays were performed and used for the modeling process. Patients received 29 (24–33) and 32 (30–35) mg/kg of amikacin in control and ECMO groups, respectively. Data were best described by a two-compartment model with first-order elimination. Inter-individual variabilities were observed on clearance, central compartment volume (V1), and peripherical compartment volume (V2). Three significant covariates explained these variabilities: Kidney Disease Improving Global Outcomes (KDIGO) stage on amikacin clearance, total body weight on V1, and ECMO support on V2. Our simulations showed that the adequate dosage of amikacin was 40 mg/kg in KDIGO stage 0 patients, while 25 mg/kg in KDIGO stage 3 patients was relevant. V-A ECMO support had only a secondary impact on amikacin pharmacokinetics, as compared to acute kidney injury.

Dates and versions

hal-04298166 , version 1 (21-11-2023)

Identifiers

Cite

Claire Pressiat, Agathe Kudela, Quentin de Roux, Nihel Khoudour, Claire Alessandri, et al.. Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation. Pharmaceutics, 2022, 14 (2), pp.289. ⟨10.3390/pharmaceutics14020289⟩. ⟨hal-04298166⟩
3 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More